To compare and contrast antibiotic use and its effects on patient outcomes before and after the implementation of a PCT protocol in the ICU at Methodist Richardson Medical Center (MRMC).

Based on previous clinical trials, current literature supports the use of PCT levels in combination with clinical assessments to help determine optimal antibiotic therapy. On May 30, 2022, MRMC launched a PCT protocol in the ICU that allows clinical pharmacy specialists to order PCT levels in certain bacterial infections. In order to determine the effects of the protocol, a retrospective quasi-experimental review will be conducted

Inclusion Criteria:

• ● Patients aged 18 years or older

  • Patients being monitored on the PCT protocol

  • ICU location status for at least part of the admission

  • Received antibiotics in the ICU for a diagnosis of:

    • Community-acquired pneumonia
    • Hospital-acquired pneumonia
    • Ventilator-associated pneumonia
    • Sepsis and/or septic shock
    • Uncomplicated bacteremia with known source
    • Chronic obstructive pulmonary disorder exacerbation
    • Asthma exacerbation

Exclusion Criteria:

• Received antibiotics in the ICU for a diagnosis of:

  • Uncomplicated skin and soft tissue infections

  • Abscess

  • Empyema

  • Bacterial infections that require prolonged antibiotic therapy (e.g., osteomyelitis, endocarditis, tuberculosis, etc.)

  • Intra-abdominal infection

  • Urinary tract infection

  • Bacterial meningitis

    • Estimated Glomerular Filtration Rate <15 mL/min
    • Requiring renal replacement therapy
    • Status post cardiac arrest/target temperature management

Patients aged 18 years or older Patients being monitored on the PCT protocol

• ICU location status for at least part of the admission

• Received antibiotics in the ICU for a diagnosis of:

  • Community-acquired pneumonia
  • Hospital-acquired pneumonia
  • Ventilator-associated pneumonia
  • Sepsis and/or septic shock
  • Uncomplicated bacteremia with known source
  • Chronic obstructive pulmonary disorder exacerbation
  • Asthma exacerbation

All information will be blinded in compliance with GCP. The investigator will make all possible efforts to ensure compliance with all policies regarding sharing of PHI or research information. Only de-identified PHI will be shared in relevant research mediums. Data obtained from this research will be presented at the Texas Society of Health-System Pharmacists 2023 Alcalde Annual Seminar. The conference will be held on April 21st-23rd, 2023. Data obtained from this research will also be written in manuscript format and submitted to a peer-reviewed journal.

1 year